MCID: SMN006
MIFTS: 25

Seminal Vesicle Tumor malady

Categories: Cancer diseases

Aliases & Classifications for Seminal Vesicle Tumor

Aliases & Descriptions for Seminal Vesicle Tumor:

Name: Seminal Vesicle Tumor 12 14
Tumor of Seminal Vesicle 12 69
Seminal Vesicle Neoplasm 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3855
NCIt 47 C39908
SNOMED-CT 64 236740006
UMLS 69 C0341767

Summaries for Seminal Vesicle Tumor

MalaCards based summary : Seminal Vesicle Tumor, also known as tumor of seminal vesicle, is related to neuropathy, congenital, with arthrogryposis multiplex and amaurosis congenita, cone-rod type, with congenital hypertrichosis. An important gene associated with Seminal Vesicle Tumor is DIRC2 (Disrupted In Renal Carcinoma 2). The drugs Lidocaine and Prilocaine have been mentioned in the context of this disorder. Related phenotype is Decreased viability in esophageal squamous lineage.

Related Diseases for Seminal Vesicle Tumor

Diseases related to Seminal Vesicle Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 81)
id Related Disease Score Top Affiliating Genes
1 neuropathy, congenital, with arthrogryposis multiplex 10.3 SDHA SDHB
2 amaurosis congenita, cone-rod type, with congenital hypertrichosis 10.3 SDHA SDHB
3 cardiac arrest 10.3 SDHA SDHB
4 glycogen storage disease ic 10.2 SDHA SDHB
5 proteus-like syndrome 10.2 KRT18 KRT7
6 bartholin's gland adenoid cystic carcinoma 10.2 KRT18 KRT7
7 prostate lymphoma 10.1 KLK3 KRT7
8 glomangioma 10.1 SDHB SYP
9 central nervous system organ benign neoplasm 10.1 DIRC2 KLK3 STK10
10 wells syndrome 10.1 KRT18 KRT7
11 mediastinal granular cell myoblastoma 10.1 KRT18 SYP
12 isolated methylmalonic acidemia 10.1 SDHA SDHB
13 non specific chronic endometritis 10.1 KRT7 SYP
14 synovitis 10.1 KRT7 SYP
15 spasmodic dysphonia 10.1 KRT7 SYP
16 sarcomatoid mesothelioma 10.1 KRT18 KRT7
17 fuchs' heterochromic uveitis 10.1 KLK3 KRT7
18 main bronchus cancer 10.1 KRT7 SYP
19 paraphimosis 10.1 KRT7 SYP
20 adult teratoma 10.1 AFP GPC3
21 uterine corpus serous adenocarcinoma 10.1 AFP GPC3
22 pediculus humanus corporis infestation 10.1 KRT18 SYP
23 pediatric liposarcoma 10.1 AFP GPC3
24 diabetes mellitus, noninsulin-dependent, 2 10.1 AFP GPC3
25 thymoma 10.1 KRT7 SYP
26 vulvar alveolar soft part sarcoma 10.1 KRT18 SYP
27 duodenal obstruction 10.1 KRT7 SYP
28 cowden syndrome 3 10.0 SDHA SDHB SYP
29 zollinger-ellison syndrome 10.0 SDHA SDHB SYP
30 distal arthrogryposis 10.0 KRT18 KRT7
31 hunter macpherson syndrome 10.0 KRT7 SYP
32 gastrointestinal stromal tumor 10.0 SDHA SDHB SYP
33 eccrine papillary adenoma 10.0 AFP KRT7
34 bagassosis 10.0 AFP KLK3
35 growth retardation hydrocephaly lung hypoplasia 10.0 KRT7 SYP
36 nonossifying fibromyxoid tumor 10.0 AFP KRT7
37 sensory organ benign neoplasm 10.0 KRT7 SYP
38 trophoblastic neoplasm 10.0 AFP KRT7
39 pheochromocytoma 10.0 SDHA SDHB SYP
40 rectum lymphoma 10.0 KRT7 SYP
41 klatskin's tumor 10.0 AFP KRT7
42 malignant teratoma 10.0 AFP KRT7
43 sphenoid sinus squamous cell carcinoma 10.0 AFP KLK3
44 uterine disease 10.0 AFP KLK3
45 steroid-induced glaucoma - borderline 10.0 EDA KLK3 KRT7
46 infiltrating renal pelvis transitional cell carcinoma 10.0 AFP SYP
47 uterine corpus epithelioid leiomyoma 10.0 AFP KLK3
48 proliferative glomerulonephritis 10.0 AFP SYP
49 persian gulf syndrome 10.0 AFP KRT7
50 prostate cancer, hereditary, x-linked 1 10.0 AFP GPC3 STK10

Graphical network of the top 20 diseases related to Seminal Vesicle Tumor:



Diseases related to Seminal Vesicle Tumor

Symptoms & Phenotypes for Seminal Vesicle Tumor

GenomeRNAi Phenotypes related to Seminal Vesicle Tumor according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.17 AFP DIRC2 EDA KLK3 KRT7 SDHA

Drugs & Therapeutics for Seminal Vesicle Tumor

Drugs for Seminal Vesicle Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 70)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
2
Prilocaine Approved Phase 4 721-50-6 4906
3 Sodium Channel Blockers Phase 4
4 Anesthetics Phase 4
5 Diuretics, Potassium Sparing Phase 4
6 Peripheral Nervous System Agents Phase 4
7 Anesthetics, Local Phase 4
8 Anti-Arrhythmia Agents Phase 4
9 Central Nervous System Depressants Phase 4
10
Choline Approved, Nutraceutical Phase 3 62-49-7 305
11
Cholecalciferol Approved, Nutraceutical Phase 2, Phase 3 67-97-0 6221 10883523 5280795
12
Ergocalciferol Approved, Nutraceutical Phase 2, Phase 3 50-14-6 5280793
13 Androgens Phase 3,Phase 2,Phase 1
14 vitamin d Phase 2, Phase 3
15 Trace Elements Phase 2, Phase 3
16 Hormone Antagonists Phase 3,Phase 2,Phase 1
17 Hormones Phase 2, Phase 3, Phase 1
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
19 Ergocalciferols Phase 2, Phase 3
20 Vitamins Phase 2, Phase 3
21 Micronutrients Phase 2, Phase 3
22 Bone Density Conservation Agents Phase 2, Phase 3
23 Calcium, Dietary Phase 2, Phase 3
24 Androgen Antagonists Phase 3,Phase 2
25 Vitamin D2 Nutraceutical Phase 2, Phase 3
26 Calciferol Nutraceutical Phase 2, Phase 3
27
Leuprolide Approved, Investigational Phase 2 53714-56-0 3911 657181
28
Dutasteride Approved, Investigational Phase 2 164656-23-9 152945 6918296
29
Testosterone Approved, Investigational Phase 2 58-22-0 6013
30
Metformin Approved Phase 2 657-24-9 14219 4091
31
Goserelin Approved Phase 2 65807-02-5 47725 5311128
32
Bicalutamide Approved Phase 2 90357-06-5 56069 2375
33
Lenograstim Approved Phase 2 135968-09-1
34
Methyltestosterone Approved Phase 2 58-18-4 6010
35
nivolumab Approved Phase 2 946414-94-4
36
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
37
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 5785 54670067
38
Docetaxel Approved May 1996, Investigational Phase 2 114977-28-5 148124 9877265
39 Fertility Agents Phase 2
40 Antimitotic Agents Phase 2
41 Antineoplastic Agents, Hormonal Phase 2
42 Steroid Synthesis Inhibitors Phase 2
43 5-alpha Reductase Inhibitors Phase 2
44
Abiraterone acetate Phase 2 154229-18-2 57336518
45 Testosterone undecanoate Phase 2
46 glucocorticoids Phase 2
47 Testosterone 17 beta-cypionate Phase 2
48
Testosterone enanthate Phase 2 315-37-7 9416
49 Anabolic Agents Phase 2
50 Cytochrome P-450 Enzyme Inhibitors Phase 2

Interventional clinical trials:

(show top 50) (show all 54)
id Name Status NCT ID Phase
1 Impact of Local Anesthesia Type on Cancer Detection Rate in Transrectal Ultrasound Guided Prostate Biopsy Completed NCT02025361 Phase 4
2 Prospective Randomized Trial of Seminal Vesicle-Sparing Prostatectomy and Nerve-Sparing Radical Prostatectomy in Men With Clinically Localized Prostate Cancer Completed NCT01825642 Phase 2, Phase 3
3 Clinical Value of FEC-PET Combined With Endorectal MRI for Pre-therapeutic Staging of Prostate Cancer Completed NCT00520546 Phase 3
4 Vitamin D Supplementation and Male Infertility: The CBG-study a Randomized Clinical Trial Completed NCT01304927 Phase 2, Phase 3
5 A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse Recruiting NCT01952223 Phase 3
6 Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer Recruiting NCT01368588 Phase 3
7 3D-Conformal Radiation vs Helical Tomotherapy in Prostate Cancer Active, not recruiting NCT00326638 Phase 3
8 Conformal Radiotherapy (CRT) Alone Versus CRT Combined With HDR BT or Stereotactic Body Radiotherapy for Prostate Cancer Not yet recruiting NCT01839994 Phase 3
9 Radical Retropubic Prostatectomy Versus Conventional External Beam Radiotherapy for Clinically Localized Prostate Cancer Suspended NCT02091661 Phase 3
10 The ELDORADO (Eligard®, Docetaxel and Radiotherapy) Study Unknown status NCT00452556 Phase 2
11 Hypofractionated Stereotactic Boost in Prostate Cancer Unknown status NCT01596816 Phase 2
12 Cone Beam CT for Daily Image Guidance - Prostate Cancer Completed NCT00188786 Phase 2
13 Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer Completed NCT01547299 Phase 2
14 External Beam Radiation Therapy - Target Volume Completed NCT00230438 Phase 2
15 Carbon Ion Radiotherapy in Treating Patients Undergoing Systemic Therapy for Oligo-metastatic Prostate Cancer Recruiting NCT02935023 Phase 2
16 Metformin Prostate Cancer Adjuvant Trial Recruiting NCT02176161 Phase 2
17 NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma Recruiting NCT02805894 Phase 1, Phase 2
18 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
19 Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial) Recruiting NCT02543255 Phase 2
20 Intensity Modulated Radiation Therapy (IMRT) Pelvic Nodes Prostate Active, not recruiting NCT00915122 Phase 1, Phase 2
21 Surgery Combined With Intensity Modulated Radiation Therapy - Image-Guided Radiation Therapy (IMRT-IGRT) in Locally-advanced Prostate Cancers Active, not recruiting NCT01148069 Phase 2
22 Safety and Efficacy Study of Hypofractionated Radiotherapy and Androgen Deprivation Therapy for Prostate Cancer Active, not recruiting NCT01505075 Phase 1, Phase 2
23 Toxicity Comparison Between Hypofractionated Radiotherapy With HDR Brachytherapy Boost Versus Standard Treatment Active, not recruiting NCT01851018 Phase 2
24 Radiation Therapy in Combination With Brachytherapy for Clinically Localized, Intermediate Risk Prostate Cancer Active, not recruiting NCT02280356 Phase 2
25 5 Fractions of Pelvic SABR With Intra Prostatic SABR Active, not recruiting NCT02911636 Phase 2
26 Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate Active, not recruiting NCT02268175 Phase 2
27 Cabazitaxel and Radiation For Patients With Pathologically Determined Stage 3 Prostate Cancer and/or Patients With PSA Elevation (>0.1- < 2.0 ng/mL) Terminated NCT01650285 Phase 2
28 FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer Terminated NCT01439542 Phase 2
29 Safety Study of Pelvic and Prostatic SIB-IMRT With Long-term Androgen Deprivation for High Risk Localized Prostate Cancer Terminated NCT01704027 Phase 2
30 Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients Withdrawn NCT02678520 Phase 2
31 Early Investigation of High Precision Radiotherapy Prior to Commencing Standard Radiotherapy for Prostate Cancer Recruiting NCT02004223 Phase 1
32 Stereotactic Hypofractionated Accelerated Radiotherapy Post-Prostatectomy Recruiting NCT02976402 Phase 1
33 Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer Active, not recruiting NCT01983709 Phase 1
34 A Phase I Trial of Neoadjuvant Stereotactic Body Radiotherapy Prior to Radical Prostatectomy for High Risk Prostate Cancer Not yet recruiting NCT02946008 Phase 1
35 Functional MR-guided Stereotactic Body Radiation Therapy of Prostate Cancer Not yet recruiting NCT01976962 Phase 1
36 Hypofractionated Whole Pelvic Radiotherapy of the Prostate Not yet recruiting NCT02546427 Phase 1
37 Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer Completed NCT02237612
38 PSA Levels and Biopsy Samples After Implant Radiation and Hormone Therapy in Patients With Stage I or Stage II Prostate Cancer Completed NCT00898326
39 Comparing Hypofractionated Radiotherapy Boost to Conventionally Fractionated Recruiting NCT02300389
40 Radiotherapy of Pelvic Lymph Nodes in High Risk Prostate Cancer - A Retrospective Analysis Recruiting NCT02998619
41 Medical and Economic Evaluation for Intermediate-risk Prostate Cancer Recruiting NCT02271659
42 Prospective Evaluation of Hypofractionation Proton Beam Therapy With Concurrent Treatment of the Prostate and Pelvic Nodes for Clinically Localized, High Risk or Unfavorable Intermediate Risk Prostate Cancer Recruiting NCT02874014
43 Hypofractionated Intensity Modulated and Image Guided Radiotherapy for Localized Prostate Cancer Recruiting NCT02651896
44 A Phase I-II Dose Escalation Study of Stereotactic Body Radiation Therapy in Patients With Localized Prostate Cancer Recruiting NCT02254746
45 Can Significant Prostate Cancer Be Detected With a Biparametric MRI? Recruiting NCT02584179
46 Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate Recruiting NCT02064036
47 Randomized MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy Recruiting NCT02307058
48 Carbon Ions Boost Followed by Pelvic Photon Radiotherapy for High Risk Prostate Cancer Active, not recruiting NCT02672449
49 Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer Active, not recruiting NCT01117935
50 Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer Active, not recruiting NCT01040624

Search NIH Clinical Center for Seminal Vesicle Tumor

Genetic Tests for Seminal Vesicle Tumor

Anatomical Context for Seminal Vesicle Tumor

Publications for Seminal Vesicle Tumor

Variations for Seminal Vesicle Tumor

Expression for Seminal Vesicle Tumor

Search GEO for disease gene expression data for Seminal Vesicle Tumor.

Pathways for Seminal Vesicle Tumor

GO Terms for Seminal Vesicle Tumor

Cellular components related to Seminal Vesicle Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mitochondrial respiratory chain complex II, succinate dehydrogenase complex (ubiquinone) GO:0005749 8.62 SDHA SDHB

Biological processes related to Seminal Vesicle Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.43 AFP GPC3 KLK3
2 tricarboxylic acid cycle GO:0006099 9.16 SDHA SDHB
3 respiratory electron transport chain GO:0022904 8.96 SDHA SDHB
4 succinate metabolic process GO:0006105 8.62 SDHA SDHB

Molecular functions related to Seminal Vesicle Tumor according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 succinate dehydrogenase (ubiquinone) activity GO:0008177 8.62 SDHA SDHB

Sources for Seminal Vesicle Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....